Skip to main content
SpringerLink
Log in

Mechanism of action of bisphosphonates

  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

In recent years, substantial progress has been made in understanding the mechanism for bisphosphonate suppression of bone turnover. Bisphosphonates can now be distinguished based on their molecular and cellular mechanisms of action. Simple bisphosphonates such as clodronate and etidronate inhibit bone resorption through induction of osteoclast apoptosis. Clodronate, and perhaps etidronate, triggers apoptosis by generating a toxic analog of adenosine triphosphate, which then targets the mitochondria, the energy center within the cell. For nitrogen-containing bisphosphonates, the direct intracellular target is the enzyme farnesyl diphosphate synthase in the cholesterol biosynthetic pathway. Its inhibition suppresses a process called protein geranylgeranylation, which is essential for the basic cellular processes required for osteoclastic bone resorption. Although nitrogen-containing bisphosphonates can induce osteoclast apoptosis, this is not necessary for their inhibition of bone resorption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rodan GA, Reszka AA: Bisphosphonate mechanism of action. Curr Mol Med 2002, 2:571–577. jThis review discusses in greater detail the clinical aspects and tissuelevel actions of N-BPs.

    Article  PubMed  CAS  Google Scholar 

  2. Reszka AA, Rodan GA: Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003, 5:65–74.

    PubMed  Google Scholar 

  3. van Beek E, Hoekstra M, van de Ruit M, et al.: Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 1994, 9:1875–1882.

    PubMed  CAS  Google Scholar 

  4. Sato M, Grasser W, Endo N, et al.: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095–2105.

    PubMed  CAS  Google Scholar 

  5. Azuma Y, Sato H, Oue Y, et al.: Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995, 16:235–245.

    Article  PubMed  CAS  Google Scholar 

  6. Masarachia P, Weinreb M, Balena R, et al.: Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996, 19:281–290.

    Article  PubMed  CAS  Google Scholar 

  7. Murakami H, Takahashi N, Sasaki T, et al.: A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995, 17:137–144.

    Article  PubMed  CAS  Google Scholar 

  8. Ito M, Amizuka N, Nakajima T, et al.: Bisphosphonate acts on osteoclasts independent of ruffled borders in osteosclerotic (oc/oc) mice. Bone 2001, 28:609–616.

    Article  PubMed  CAS  Google Scholar 

  9. Salo J, Lehenkari P, Mulari M, et al.: Removal of osteoclast bone resorption products by transcytosis. Science 1997, 276:270–273.

    Article  PubMed  CAS  Google Scholar 

  10. van Beek ER, Lowik CW, Papapoulos SE: Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002, 30:64–70.

    Article  PubMed  Google Scholar 

  11. Frith JC, Rogers MJ: Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 2003, 18:204–212.

    Article  PubMed  CAS  Google Scholar 

  12. Halasy-Nagy JM, Rodan GA, Reszka AA: Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001, 29:553–559. This paper demonstrates the separation of bisphosphonates, based on suppression of bone resorption through induction of osteoclast apoptosis (eg, clodronate and etidronate) versus inhibition of osteoclast function (eg, N-BPs).

    Article  PubMed  CAS  Google Scholar 

  13. Klein G, Martin JB, Satre M: Methylenediphosphonate, a metabolic poison in dictyostelium discoideum. Phosphorus-31 NMR evidence for accumulation of adenosine 5′-(beta, gamma-methylenetriphosphate) and diadenosine 5′,5′′′-P1,P4-(P2,P3-methylenetetraphosphate). Biochemistry 1988, 27:1897–1901.

    Article  CAS  Google Scholar 

  14. Auriola S, Frith J, Rogers MJ, et al.: Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 1997, 704:187–195.

    Article  PubMed  CAS  Google Scholar 

  15. Frith JC, Monkkonen J, Blackburn GM, et al.: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12:1358–1367. This paper provides the first in vivo proof for the mechanism of action of clodronate in osteoclasts and macrophages.

    Article  PubMed  CAS  Google Scholar 

  16. Frith JC, Monkkonen J, Auriola S, et al.: The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001, 44:2201–2210.

    Article  PubMed  CAS  Google Scholar 

  17. Hughes DE, Wright KR, Uy HL, et al.: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10:1478–1487.

    Article  PubMed  CAS  Google Scholar 

  18. Selander KS, Monkkonen J, Karhukorpi EK, et al.: Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996, 50:1127–1138.

    PubMed  CAS  Google Scholar 

  19. Reszka AA, Halasy Nagy JM, Masarachia PJ, et al.: Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosispromoting kinase. J Biol Chem 1999, 274:34967–34973.

    Article  PubMed  CAS  Google Scholar 

  20. Lehenkari PP, Kellinsalmi M, Napankangas JP, et al.: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002, 61:1255–1262.

    Article  PubMed  CAS  Google Scholar 

  21. Biller SA, Forster C, Gordon EM, et al.: Isoprenoid (phosphinylmethyl) phosphonates as inhibitors of squalene synthetase. J Med Chem 1988, 31:1869–1871.

    Article  PubMed  CAS  Google Scholar 

  22. Fisher JE, Rogers MJ, Halasy JM, et al.: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999, 96:133–138. This paper provides the first demonstration that protein geranylgeranylation is the critical metabolic process inhibited by the N-BPs in the osteoclast. It demonstrates that restoration of geranylgeranylation, but not farnesylation or cholesterol synthesis, can restore osteoclast function in the presence of alendronate.

    Article  PubMed  CAS  Google Scholar 

  23. Luckman SP, Coxon FP, Ebetino FH, et al.: Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998, 13:1668–1678.

    Article  PubMed  CAS  Google Scholar 

  24. van Beek E, Lowik C, van der Pluijm G, et al.: The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999, 14:722–729. This paper demonstrates the importance of protein geranylgeranylation to osteoclast function and also demonstrates that restoring protein geranylgeranylation can block the N-BPs effects on bone resorption.

    Article  Google Scholar 

  25. Bergstrom JD, Bostedor RG, Masarachia PJ, et al.: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000, 373:231–241.

    Article  PubMed  CAS  Google Scholar 

  26. van Beek E, Pieterman E, Cohen L, et al.: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999, 264:108–111.

    Article  PubMed  Google Scholar 

  27. Dunford JE, Thompson K, Coxon FP, et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235–242.

    PubMed  CAS  Google Scholar 

  28. Fisher JE, Rodan GA, Reszka AA: In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000, 141:4793–4796. This paper provides the first in vivo proof for N-BP suppression of the mevalonate pathway selectively in osteoclasts. It also shows that osteoclast numbers rise immediately following N-BP treatment, but not clodronate or etidronate.

    Article  PubMed  CAS  Google Scholar 

  29. Woo JT, Kasai S, Stern PH, et al.: Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res 2000, 15:650–662.

    Article  PubMed  CAS  Google Scholar 

  30. Dunford JE, Ebetino FH, Rogers MJ: The mechanism of inhibition of farnesyl diphosphate synthase by nitrogen-containing bisphosphonates. Bone 2002, 30:40S.

    Article  Google Scholar 

  31. Luckman SP, Hughes DE, Coxon FP, et al.: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581–589.

    Article  PubMed  CAS  Google Scholar 

  32. Coxon FP, Helfrich MH, Van’t Hof R, et al.: Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000, 15:1467–1476.

    Article  PubMed  CAS  Google Scholar 

  33. Alakangas A, Selander K, Mulari M, et al.: Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002, 70:40–47.

    Article  PubMed  CAS  Google Scholar 

  34. Glantschnig H, Rodan GA, Reszka AA: Alendronate mechanism of action: the role of geranylgeranylation in p70S6 kinase-dependent osteoclast survival. Bone 2002, 30:41S.

    Google Scholar 

  35. Graves JD, Gotoh Y, Draves KE, et al.: Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J 1998, 17:2224–2234.

    Article  PubMed  CAS  Google Scholar 

  36. Glantschnig H, Rodan GA, Reszka AA: Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J Biol Chem 2002, 277:42987–42996.

    Article  PubMed  CAS  Google Scholar 

  37. Benford HL, Frith JC, Auriola S, et al.: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999, 56:131–140.

    PubMed  CAS  Google Scholar 

  38. Schenk R, Merz WA, Muhlbauer R, et al.: Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973, 11:196–214.

    Article  PubMed  CAS  Google Scholar 

  39. Selander K, Lehenkari P, Vaananen HK: The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 1994, 55:368–375.

    Article  PubMed  CAS  Google Scholar 

  40. Kim TW, Yoshida Y, Yokoya K, et al.: An ultrastructural study of the effects of bisphosphonate administration on osteoclastic bone resorption during relapse of experimentally moved rat molars. Am J Orthod Dentofacial Orthop 1999, 115:645–653.

    Article  PubMed  CAS  Google Scholar 

  41. Zimolo Z, Wesolowski G, Rodan GA: Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 1995, 96:2277–2283.

    Article  PubMed  CAS  Google Scholar 

  42. Zhao H, Ettala O, Vaananen HK: Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTPbinding rab proteins. Biochem Biophys Res Commun 2002, 293:1060–1065.

    Article  PubMed  CAS  Google Scholar 

  43. Zhao H, Laitala Leinonen T, Parikka V, et al.: Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption. J Biol Chem 2001, 276:39295–39302.

    Article  PubMed  CAS  Google Scholar 

  44. Zhang D, Udagawa N, Nakamura I, et al.: The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995, 108:2285–2292.

    PubMed  CAS  Google Scholar 

  45. Razzouk S, Lieberherr M, Cournot G: Rac-GTPase, osteoclast cytoskeleton and bone resorption. Eur J Cell Biol 1999, 78:249–255.

    PubMed  CAS  Google Scholar 

  46. Chellaiah MA, Soga N, Swanson S, et al.: RhoA is critical for osteoclast podosome organization, motility, and bone resorption. J Biol Chem 2000, 275:11993–12002.

    Article  PubMed  CAS  Google Scholar 

  47. Backlund PS Jr: Post-translational processing of RhoA. Carboxyl methylation of the carboxyl-terminal prenylcysteine increases the half-life of RhoA. J Biol Chem 1997, 272:33175–33180.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Endocrinology and Bone Biology, Merck Research Laboratories, 19846, West Point, PA, USA

    Alfred A. Reszka PhD

Authors
  1. Alfred A. Reszka PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gideon A. Rodan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reszka, A.A., Rodan, G.A. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1, 45–52 (2003). https://doi.org/10.1007/s11914-003-0008-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-003-0008-5

Keywords

Search

Navigation